Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01  ChemPort single article sales feature unavailable
 NEWS  3  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced
 NEWS  4  APR 07  STN is raising the limits on saved answers
 NEWS  5  APR 24  CA/CAplus now has more comprehensive patent assignee
                  information
 NEWS  6  APR 26  USPATFULL and USPAT2 enhanced with patent
                  assignment/reassignment information
 NEWS  7  APR 28  CAS patent authority coverage expanded
 NEWS  8  APR 28  ENCOMPLIT/ENCOMPLIT2 search fields enhanced
 NEWS  9  APR 28  Limits doubled for structure searching in CAS
                  REGISTRY
 NEWS 10  MAY 08  STN Express, Version 8.4, now available
 NEWS 11  MAY 11  STN on the Web enhanced
 NEWS 12  MAY 11  BEILSTEIN substance information now available on
                  STN Easy
 NEWS 13  MAY 14  DGENE, PCTGEN and USGENE enhanced with increased
                  limits for exact sequence match searches and
                  introduction of free HIT display format
 NEWS 14  MAY 15  INPADOCDB and INPAFAMDB enhanced with Chinese legal
                  status data
 NEWS 15  MAY 28  CAS databases on STN enhanced with NANO super role in
                  records back to 1992
 NEWS 16  JUN 01  CAS REGISTRY Source of Registration (SR) searching
                  enhanced on STN

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:04:55 ON 11 JUN 2009

```
=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                             ENTRY    SESSION
FULL ESTIMATED COST                                           0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:05:13 ON 11 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    9 JUN 2009  HIGHEST RN 1154896-16-8
DICTIONARY FILE UPDATES:   9 JUN 2009  HIGHEST RN 1154896-16-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s itraconazole/cn
L1            1 ITRACONAZOLE/CN

=> s ketoconazole/cn
L2            1 KETOCONAZOLE/CN

=> file hacaplus
'HACAPLUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                             ENTRY    SESSION
FULL ESTIMATED COST                                          11.18      11.40

FILE 'HCAPLUS' ENTERED AT 12:05:50 ON 11 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
```

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2009 VOL 150 ISS 24
FILE LAST UPDATED: 10 Jun 2009 (20090610/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1 or l2
          3320 L1
          4473 L2
L3        6601 L1 OR L2

=> s "water-soluble polymer" and (alcohol or acetone)
       2900999 "WATER"
        287080 "WATERS"
       2962019 "WATER"
                 ("WATER" OR "WATERS")
        132465 "SOLUBLE"
          2621 "SOLUBLES"
        134936 "SOLUBLE"
                 ("SOLUBLE" OR "SOLUBLES")
       1264738 "POLYMER"
       1001748 "POLYMERS"
       1690269 "POLYMER"
                 ("POLYMER" OR "POLYMERS")
          3806 "WATER-SOLUBLE POLYMER"
                 ("WATER"(W)"SOLUBLE"(W)"POLYMER")
        319417 ALCOHOL
        195247 ALCOHOLS
        476244 ALCOHOL
                 (ALCOHOL OR ALCOHOLS)
        199189 ACETONE
           682 ACETONES
        199508 ACETONE
                 (ACETONE OR ACETONES)
L4         657 "WATER-SOLUBLE POLYMER" AND (ALCOHOL OR ACETONE)

=> s l3 and l4
L5           2 L3 AND L4

=> d l5 1-2 ibib, abs

L5   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:125255  HCAPLUS
DOCUMENT NUMBER:         148:198652
TITLE:                   Composition comprising water-soluble
                         polymer and nano-sized active agent
INVENTOR(S):             Farr, Isaac; Rivera, Leslie; Diaz-Felipe, Ricardo G.;
                         Valentin-Sivico, Javier; Tirado, Saul; Figueroa, Iddys
                         D.; Kane, Kevin Michael; Aponte, Mirayda
```

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080026062	A1	20080131	US 2006-496873	20060731
PRIORITY APPLN. INFO.:			US 2006-496873	20060731

AB The present invention is directed to a particulate pharmaceutical composition The particulate pharmaceutical composition can comprise a water-soluble or partially water-soluble polymer matrix; and a plurality of nano-sized particles of active agent which are sparingly water-soluble to water-insol. dispersed in the water-soluble or partially water-soluble polymer matrix. The particulate pharmaceutical composition can be micronized or in the form of a film that can be rolled up. If micronized, the individual micron-sized particles can have a plurality of nano-sized particles present in the micron-sized particles. Thus, glyburide was completely dissolved in a solution of chloroform 12.2 %, ethanol 48.8%, and water 39% at a concentration of 3.3 mg/mL to form a drug solution The drug solution was then placed onto a film of pullulan where the chloroform and ethanol were allowed to evaporate As these lower b.p. solvents evaporated, the glyburide precipitated in the form of nanosized particles. The water that remained dissolved the pullulan to yield a paste containing the nanosized glyburide particles. The paste was then lyophilized, dried under hard-vacuum, and ground to yield the final micron-size drug product of nanosized particles dispersed throughout the micron-sized pullulan matrix.

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:833058 HCAPLUS
DOCUMENT NUMBER: 135:362595
TITLE: Gastric pH-independent pharmaceutical composition containing itraconazole with improved solubility
INVENTOR(S): Wang, Hun-Sik; Jang, Sun-Woo; Bae, Woong-Tak; Kim, Jeong-Hoon; Kwon, Jong-Won
PATENT ASSIGNEE(S): Dong A Pharma. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085135	A1	20011115	WO 2001-KR657	20010420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
KR 2001097244	A	20011108	KR 2000-21137	20000421
PRIORITY APPLN. INFO.:			KR 2000-21137 A	20000421

```
AB   The present invention relates to a pharmaceutical composition containing
     itraconazole and its preparation, more particularly, to a pharmaceutical
composition
     containing itraconazole obtained by dissolving in a solvent and a
     pH-independent water-soluble polymer and spray-drying the resulting solution
     The pharmaceutical composition containing itaconazole increases the solubility
of
     itaconazole and prevents the reduction of solubility of itraconazole caused as
pH
     increases.  As a result, the pharmaceutical composition improves the
     bioavailability of itraconazole and minimizes absorption variance
     dependent on the pH of the individual stomach.  Also, the pharmaceutical
     composition can be prepared by a single-process, such as spray-spraying.  Along
     with 100 g of Me cellulose and 100 g itraconazole was dissolved in 1750 g
     a solvent mixture of EtOH and CH2Cl2 in volume ratios of 1:1.  Talc (1 g) was
     well dispersed in the solution to give a spray drying solution  With the aid of
     a spray-drier, the spray-drying solution was spray-dried under the following
     conditions to give an itraconazole-containing pharmaceutical composition
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 12:04:55 ON 11 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 12:05:13 ON 11 JUN 2009
L1             1 S ITRACONAZOLE/CN
L2             1 S KETOCONAZOLE/CN

     FILE 'HCAPLUS' ENTERED AT 12:05:50 ON 11 JUN 2009
L3          6601 S L1 OR L2
L4           657 S "WATER-SOLUBLE POLYMER" AND (ALCOHOL OR ACETONE)
L5             2 S L3 AND L4

=> s coated(S)particle?
        565245 COATED
             2 COATEDS
        565247 COATED
                  (COATED OR COATEDS)
       1428221 PARTICLE?
L6       42551 COATED(S)PARTICLE?

=> s l3 and l6
L7           11 L3 AND L6

=> d l7 1-11 ibib, abs

L7   ANSWER 1 OF 11  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2007:385013  HCAPLUS
DOCUMENT NUMBER:          146:387123
TITLE:                    Microparticles with modified release of at least one
                          active principle and oral galenic form comprising same
INVENTOR(S):              Dargelas, Frederic; Guimberteau, Florence; Castan,
                          Catherine; Meyrueix, Remi; Soula, Gerard
PATENT ASSIGNEE(S):       Flamel Technologies, Fr.
SOURCE:                   PCT Int. Appl., 50pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007036671	A2	20070405	WO 2006-FR50944	20060927
WO 2007036671	A3	20070524		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
FR 2891459	A1	20070406	FR 2005-52985	20050930
FR 2891459	B1	20071228		
CA 2624372	A1	20070405	CA 2006-2624372	20060927
EP 1931320	A2	20080618	EP 2006-831231	20060927
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009510036	T	20090312	JP 2008-532838	20060927
CN 101277684	A	20081001	CN 2006-80036080	20080328

PRIORITY APPLN. INFO.: FR 2005-52985 A 20050930
WO 2006-FR50944 W 20060927

AB The invention concerns microparticle systems with modified release of oral active principle(s). The invention aims at providing a novel multimicroparticle galenic system operating in accordance with a dual time-dependent and pH-dependent release mechanism, which enables the following three parameters to be adjusted independently of one another: (a) the latent period preceding the release of the active principle in the stomach; (b) the pH triggering the release of the active principle in the intestine; (c) the release speed of the active principle. This is achieved through the use of coated microparticles made from particles of active principle each coated with two coating films A and B. Film A comprises: film-forming (co)polymer (A1) insol. in fluids of the gastrointestinal tract, Et cellulose (co)polymer (A2) soluble in fluids of the gastrointestinal tract, plasticizing polyvinylpyrrolidone (A3), and castor oil and optionally a surfactant and/or magnesium stearate lubricant (A4). Film B comprises a hydrophilic polymer (B1) bearing ionized groups with neutral pH (Eudragit L100-55) and a hydrophobic compound (B2) (Lubritab). Metformin hydrochloride and povidone were dissolved in water and spray-dried over neural microspheres. The microspheres were then coated to obtain prolonged-release metformin microparticles.

L7 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:83585 HCAPLUS
DOCUMENT NUMBER: 146:158190
TITLE: SERS-based cytochrome P 450 assay for high-throughput screening applications
INVENTOR(S): Haddach, Mustapha; Naeve, Gregory S.
PATENT ASSIGNEE(S): Parallax Biosystems, USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007011778	A2	20070125	WO 2006-US27486	20060712
WO 2007011778	A3	20070524		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080233606	A1	20080925	US 2008-16915	20080422
PRIORITY APPLN. INFO.:			US 2005-700757P	P 20050718
			WO 2006-US27486	A2 20060712

AB Provided herein is a Raman spectroscopy-based assay useful to identify modulators of an enzyme. In particular, SERS-based methods are used to determine the activity of cytochrome P 450 by monitoring the appearance of metabolites that arise from enzyme-specific reactions using probe substrates for each of the cytochrome P 450 enzymes.

L7 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:608715 HCAPLUS
DOCUMENT NUMBER: 145:89975
TITLE: Pharmaceutical composition containing coated , floating particles
INVENTOR(S): Grenier, Pascal; Taillemite, Julien; Serreau, Severine; Nhamias, Alain
PATENT ASSIGNEE(S): Jagotec AG, Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063858	A1	20060622	WO 2005-EP13670	20051215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1835893	A1	20070926	EP 2005-820646	20051215

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

US 20080317841	A1	20081225	US 2008-793180	20080902
PRIORITY APPLN. INFO.:			GB 2004-27455	A 20041215
			WO 2005-EP13670	W 20051215

AB A dosage form exhibits delayed transit time through the gastrointestinal

tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating. Thus, the inner core contained diltiazem-HCl 2.78, Methocel K100M 8.35, Avicel PH102 5.57, Compritol 888ATO 11.14, and Plasdone K29-32 1.36%.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:541106 HCAPLUS
DOCUMENT NUMBER: 144:495431
TITLE: Oral itraconazole preparations
INVENTOR(S): Oshima, Takao; Sonoda, Ryoichi; Okuma, Moriyuki
PATENT ASSIGNEE(S): Kaken Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006143683	A	20060608	JP 2004-338572	20041124

PRIORITY APPLN. INFO.: JP 2004-338572 20041124
AB Particles (average diameter 10-60 μm) are spray- coated with a solution containing itraconazole and enteric-soluble polymers to give coated particles, which are granulated and compressed into tablets or filled into capsules. The prepns. provide improved elution properties in an acidic solution in the stomach.

L7 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1311702 HCAPLUS
DOCUMENT NUMBER: 144:57525
TITLE: Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti, Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.
PATENT ASSIGNEE(S): UMD, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 126,863
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050276836	A1	20051215	US 2005-180076	20050712
US 6197327	B1	20010306	US 1998-79897	19980515
US 6086909	A	20000711	US 1999-249963	19990212
US 6572874	B1	20030603	US 2000-626025	20000727
NZ 508130	A	20020301	NZ 2000-508130	20001113
AU 765269	B2	20030911	AU 2001-54192	20010703
US 20030049302	A1	20030313	US 2002-226667	20020821
US 6982091	B2	20060103		
US 20040005345	A1	20040108	US 2003-349029	20030122
US 6905701	B2	20050614		
US 20040043071	A1	20040304	US 2003-600849	20030620
US 20050249774	A1	20051110	US 2005-126863	20050510

PRIORITY APPLN. INFO.:

US 1997-49325P	P	19970611
US 1998-79897	A2	19980515
US 1999-249963	A2	19990212
US 2000-626025	A2	20000727
US 2002-226667	A2	20020821
US 2003-349029	A2	20030122
US 2003-600849	A2	20030620
US 2004-587454P	P	20040712
US 2005-126863	A2	20050510
AU 1998-76976	A3	19980610
NZ 1998-502120	A1	19980610
US 1999-146218P	P	19990728
US 2001-315877P	P	20010829
US 2002-390748P	P	20020621

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.

L7 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:981078 HCAPLUS

DOCUMENT NUMBER: 144:27295

TITLE: Stabilizer choice for rapid dissolving high potency itraconazole particles formed by evaporative precipitation into aqueous solution

AUTHOR(S): Sinswat, Prapasri; Gao, Xiaoxia; Yacaman, Miguel J.; Williams, Robert O.; Johnston, Keith P.

CORPORATE SOURCE: College of Pharmacy, University of Texas at Austin, Austin, TX, 78712, USA

SOURCE: International Journal of Pharmaceutics (2005), 302(1-2), 113-124
CODEN: IJPHDE; ISSN: 0378-5173

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The objective of this study was to investigate the influence of stabilizer type on the physicochem. properties, including dissoln., of ultra-high potency powders containing itraconazole (ITZ) formed by evaporative precipitation into aqueous solution (EPAS). ITZ was dissolved in dichloromethane, which was then atomized through a heated coil at 80° into an aqueous solution over precise periods of time. Stabilizers were present in either the aqueous, organic or both phases. The dispersions were centrifuged and the supernatant was removed. Three hydrophilic stabilizers were investigated, including polysorbate 80, polyvinyl pyrrolidone and poloxamer 407. Rapid dissolving ultra-high potency of ITZ powders was successfully produced. Greater than 80% of ITZ was dissolved in 5 min compared to only 13% of ITZ bulk powders. The resulting stabilizer-coated drug particles had high drug-to-stabilizer ratios greater than 12, corresponding to potencies (weight drug/weight drug + weight surfactant) as high as 93%. An increase in dissoln. rate was correlated with the amount of stabilizer adsorbed and the wettability. The combination of polysorbate 80 and poloxamer 407 present in the aqueous and organic phases, resp., was superior in achieving high wetting and rapid dissolving ITZ powders. The ability to control the adsorption behavior of stabilizers by using synergistic combinations affords the opportunity to achieve high dissoln. rates with

higher potencies compared to previously reported values.
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:182113 HCAPLUS
DOCUMENT NUMBER: 142:266783
TITLE: Formulation to render an antimicrobial drug potent against organisms considered to be drug resistant
INVENTOR(S): Rabinow, Barrett; White, Randy; Sun, Chong-Son; Wong, Joseph Chung Tak; Kipp, James E.; Doty, Mark J.; Rebbeck, Christine; Papadopoulos, Pavlos George
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 270,268.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050048126	A1	20050303	US 2004-834541	20040429
US 20020127278	A1	20020912	US 2001-874637	20010605
US 6869617	B2	20050322		
US 20030003155	A1	20030102	US 2001-953979	20010917
US 6951656	B2	20051004		
US 20030044433	A1	20030306	US 2001-35821	20011019
US 6977085	B2	20051220		
US 20030031719	A1	20030213	US 2001-21692	20011212
US 20030206959	A9	20031106		
US 6884436	B2	20050426		
US 20030096013	A1	20030522	US 2002-246802	20020917
US 20030072807	A1	20030417	US 2002-270268	20021011
ZA 2003004742	A	20040824	ZA 2003-4742	20030619
IN 2006DN01243	A	20070817	IN 2006-DN1243	20060308

PRIORITY APPLN. INFO.:

US 2000-258160P	P	20001222
US 2001-874637	A2	20010605
US 2001-953979	A2	20010917
US 2001-35821	A2	20011019
US 2001-21692	A2	20011212
US 2002-246802	A2	20020917
US 2002-270268	A2	20021011
US 2003-466354P	P	20030429
WO 2004-US35335	W	20041025

AB The present invention relates to compns. of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, nonionic surfactants, biol. derived surfactants, and amino acids and their derivs. The particles have a volume-weighted mean particle size of less than 5 μm as measured by laser diffractometry. A composition comprised itraconazole, Na deoxycholate monohydrate, Poloxamer 188, glycerin, NaOH/HCl to adjust pH, and sterile water.

L7 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965031 HCAPLUS
DOCUMENT NUMBER: 141:400955

TITLE: Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug

INVENTOR(S): Rabinow, Barrett E.; White, Randy; Sun, Chong-Son; Wong, Joseph Chung Tak; Kipp, James E.; Doty, Mark J.; Rebbeck, Christine L.; Papadopoulos, Pavlos

PATENT ASSIGNEE(S): Baxter International Inc., USA

SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 13

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096180	A1	20041111	WO 2004-US13268	20040429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004234003	A1	20041111	AU 2004-234003	20040429
CA 2523151	A1	20041111	CA 2004-2523151	20040429
EP 1617818	A1	20060125	EP 2004-760446	20040429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009929	A	20060425	BR 2004-9929	20040429
CN 1794975	A	20060628	CN 2004-80011668	20040429
JP 2006525345	T	20061109	JP 2006-513447	20040429
IN 2005DN04618	A	20070824	IN 2005-DN4618	20051013
ZA 2005008467	A	20060927	ZA 2005-8467	20051019
MX 2005011607	A	20051215	MX 2005-11607	20051028
IN 2006DN01243	A	20070817	IN 2006-DN1243	20060308

PRIORITY APPLN. INFO.:

US 2003-466354P	P	20030429
WO 2004-US13268	W	20040429
WO 2004-US35335	W	20041025

AB The present invention relates to compns. of submicron-to-micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron-to-micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of ionic surfactants, nonionic surfactants, biol. derived surfactants, and amino acids and their derivs. The particles have a volume-weighted mean particle size of less than 5 μm as measured by laser diffractometry. For example, a 1% itraconazole suspension with deoxycholic acid coating was prepared containing itraconazole 1.0 g, sodium deoxycholate monohydrate 0.1 g, Poloxamer 188 0.1 g, glycerin 2.2 g, water to 100 mL, and sodium hydroxide (0.1N or 1.0N) and hydrochloric acid (0.1N or 1.0N) for adjustment to a pH of 8.0.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:119766 HCAPLUS

DOCUMENT NUMBER: 140:152014
TITLE: Enteric coated oral pharmaceutical compositions of acid-unstable drugs
INVENTOR(S): Deshpande, Jayant Venkatesh; Gupte, Vandana Sandeep; Kadam, Vaishali Madhukar; Gosar, Chandrakant Thakarsi; Deshmukh, Satish Ramachandra; Gupte, Rajan Vitthal; Tamhankar, Vijay Ramachandra
PATENT ASSIGNEE(S): Kopran Research Laboratories Limited, India
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040028737	A1	20040212	US 2002-216315	20020812
PRIORITY APPLN. INFO.:			US 2002-216315	20020812

AB Enteric coated stable oral pharmaceutical compns. of acid-unstable drugs are described. The enteric coating is a bilayer with a pH gradient across its thickness comprising an inner layer of neutral or near neutral pH 7-7.5 and an outer layer of acidic pH 2-6. The enteric coating is first carried out at neutral or near neutral pH of 7-7.5 to form an inner layer of neutral or near neutral pH and then at acidic pH of 2-6 to form an outer layer of acidic pH. Tablets of the following composition were prepared: omeprazole 10.30, anhydrous lactose 55.00, Mg stearate 1.00, talc 1.00, colloidal silicon dioxide 0.50, microcryst. cellulose 17.00, corn starch 10.00, and Povidone 3.00 mg. The tablets were enteric coated with the following aqueous organic dispersion of enteric coating material at neutral pH 7:
methacrylate copolymer type C 0.4, PEG-600 0.04, Polysorbate-80 0.02, titanium dioxide 0.05, and talc 0.165 kg, iso-Pr alc. 4.0 and Water 0.375 L.

L7 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:274750 HCAPLUS
DOCUMENT NUMBER: 138:292758
TITLE: Itoraconazole oral solid compositions
INVENTOR(S): Teramae, Junya; Hashimoto, Toshikazu; Fujii, Hironaga; Tsujita, Akio; Yasuoka, Takaharu
PATENT ASSIGNEE(S): Kobayashi Kako KK, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003104892	A	20030409	JP 2001-299294	20010928
PRIORITY APPLN. INFO.:			JP 2001-299294	20010928

AB The invention provides an itoraconazole oral solid composition, e.g. a hard gelatin capsule and a tablet, wherein the composition has a core particle having a particle size of ≤ 500 μm, coated with itoraconazole, a hydrophilic polymer and an aggregation inhibiting agent. A hard gelatin capsule was prepared from itoraconazole 50, lactose/crystalline cellulose sphere (180-300 μm) 75, hydroxypropyl Me cellulose 75, and polyethylene glycol 9.5 mg.

L7 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:615379 HCAPLUS
DOCUMENT NUMBER: 137:159351
TITLE: Oral itraconazole formulations
INVENTOR(S): Namburi, Ranga Raju; Kerr, John Elgin
PATENT ASSIGNEE(S): DSM N.V., Neth.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062318	A2	20020815	WO 2002-NL80	20020201
WO 2002062318	A3	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020150620	A1	20021017	US 2001-933032	20010820
US 6663897	B2	20031216		
CA 2437372	A1	20020815	CA 2002-2437372	20020201
AU 2002233822	A1	20020819	AU 2002-233822	20020201
EP 1357899	A2	20031105	EP 2002-700887	20020201
EP 1357899	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521897	T	20040722	JP 2002-562325	20020201
AT 369840	T	20070915	AT 2002-700887	20020201
EP 1842532	A2	20071010	EP 2007-13191	20020201
EP 1842532	A3	20090422		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
MX 2003006980	A	20041015	MX 2003-6980	20030805
US 20040115266	A1	20040617	US 2004-467435	20040205

PRIORITY APPLN. INFO.:			
US 2001-266653P	P	20010206	
US 2001-933032	A	20010820	
EP 2002-700887	A3	20020201	
WO 2002-NL80	W	20020201	

AB A method of manufacturing an itraconazole oral dosage from that is substantially free of residual methylene chloride comprises the steps of: (a) providing a working solution comprising an alc., a strong acid (preferably an inorg. acid or organic sulfonic acid), itraconazole, a water-soluble polymer, and water, with the itraconazole and the strong acid preferably present in the working solution in a ratio of 1 Mol itraconazole to 1-3 Mol acid; (b) providing particles formed from a pharmaceutically acceptable core material; (c) combining the working solution with the particles to produce itraconazole-coated particles; (d) drying the itraconazole-coated particles; and(e) forming the dried itraconazole-coated particles into an itraconazole oral dosage form that is substantially free of residual methylene chloride. A composition contained microcryst. cellulose spheres 36.28, micronized itraconazole 18.86, HPMC 42.45, titanium dioxide 0.85, and HCl (37%) 1.56.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 12:04:55 ON 11 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 12:05:13 ON 11 JUN 2009
L1             1 S ITRACONAZOLE/CN
L2             1 S KETOCONAZOLE/CN

     FILE 'HCAPLUS' ENTERED AT 12:05:50 ON 11 JUN 2009
L3          6601 S L1 OR L2
L4           657 S "WATER-SOLUBLE POLYMER" AND (ALCOHOL OR ACETONE)
L5             2 S L3 AND L4
L6         42551 S COATED(S)PARTICLE?
L7            11 S L3 AND L6

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                58.95      70.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -10.66     -10.66

STN INTERNATIONAL LOGOFF AT 12:10:13 ON 11 JUN 2009
```